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Overall resistance rates > Across EU/EEA member states, ten-year data for the four GN bacteria shows stable levels of carbapenem resistance for E. coli (<1%), P. aeruginosa (20%), and K. pneumoniae (8%), and a downward, but variable, trend in the proportion of CR Acinetobacter spp. (Figure  1 ). Note that data on CR Acinetobacter spp. have only been collected since 2012 (in response to concern about increasing prevalence). 6 > In the EU5 (France, Germany, Italy, Spain, UK), carbapenem resistance trends in E. coli and P. aeruginosa were similar to rates across the EU/EEA, though there was a marked increase in CR K. pneumoniae from 2009 (<1% to 8%) (Figure 1 ). 6
The EARS-Net database contained epidemiological data for E. coli from 2000, for K. pneumoniae and P. aeruginosa from 2005, and for Acinetobacter spp. from 2012. 6
Country-specific resistance rates > Though resistance rates averaged across all countries in the EU/EEA give a broad sense of the level of resistance, this may obscure any inter-country variability. Figure 2 illustrates that the proportions of GN isolates that tested resistant were highly variable across the EU/EEA in 2016. 6 > The call-out box on each map gives the carbapenem resistance rate in the highest resistance country. 6 The number of isolates vs. the proportion carbapenem resistant > High resistance rates do not necessarily translate into a high disease burden -if infections due to a highly resistant bacteria are very rare, the detrimental effect on society will be low. − Over the past five years, none of the species have exhibited both high resistance and high prevalence (Figure 3) . 6 Though carbapenem resistance rates in Acinetobacter spp. were high, the number of infections were relatively low. Conversely, carbapenem resistance in E. coli were very low, but the number of infections was far greater than for the other bacteria.
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Mortality due to CR infections > The literature search did not identify recent, high-quality systematic literature reviews analysing the attributable burden of CR GN infections in Europe. From reviews that used data from global sources, the following mortality rates were reported: et al., 2018. 9 − CR E. coli -the search did not identify reviews reporting on the mortality attributable to CR E. coli.
. Figure 1 . Proportion resistant > Rates of carbapenem resistance in GN bacteria are high in many parts of Europe, with eastern, southern, and Baltic countries most affected. 6 − The recent rise of CR bacteria is largely due to the dissemination of carbapenemases, enzymes capable of hydrolysing the antibiotic. − CR Acinetobacter spp. infections were associated with the highest mortality, though reviews using solely European data were not found. > Presently, highly resistant bacteria are not highly prevalent -this is prone to rapid change due to mutation or through gene transmission between bacteria. 10 − Should this happen, medicine will regress to a post-antibiotic era, meaning mortality from mild infections will rise, routine surgery will become highly unsafe, and the world will incur enormous economic costs. 1,2 > The insidious spread of CR GN bacteria in Europe emphasises the need for prudent antibiotic stewardship by physicians and patients, novel research by industry, and increased funding and streamlined regulatory approval for new antibiotics by decision makers and regulatory bodies. > High quality systematic literature reviews and meta-analyses on infection-associated mortality are required to fully illustrate the attributable disease burden of CR infections in Europe.
Conclusions
